AZD-6918

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206220

CAS#: 905585-60-6

Description: AZD6918 is a novel potent and selective inhibitor of the Trk tyrosine kinases. AZD-6918 attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo. AZD6918 inhibited wild-type TrkB-induced cell migration and cell growth.

Chemical Structure

img
AZD-6918
CAS# 905585-60-6
Handing Instruction

Theoretical Analysis

MedKoo Cat#: 206220
Name: AZD-6918
CAS#: 905585-60-6
Chemical Formula: C20H20F2N6O
Exact Mass: 398.1667
Molecular Weight: 398.4178
Elemental Analysis: C, 60.29; H, 5.06; F, 9.54; N, 21.09; O, 4.02

Size Price Shipping out time Quantity
Inquire bulk and customized quantity
Pricing updated 2021-03-01. Prices are subject to change without notice.

AZD-6918 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

Synonym: AZD-6918; AZD6918; AZD 6918.

IUPAC/Chemical Name: (S)-5-Fluoro-2-[[1-(4-fluorophenyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]nicotinonitrile

InChi Key: QRAQXWWNHQMCBH-LBPRGKRZSA-N

InChi Code: InChI=1S/C20H20F2N6O/c1-11(2)29-18-9-17(27-28-18)25-20-16(22)8-14(10-23)19(26-20)24-12(3)13-4-6-15(21)7-5-13/h4-9,11-12H,1-3H3,(H3,24,25,26,27,28)/t12-/m0/s1

SMILES Code: N#CC1=C(N[C@H](C2=CC=C(F)C=C2)C)N=C(NC3=NNC(OC(C)C)=C3)C(F)=C1

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 398.4178 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ. Trk inhibitor attenuates the
BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and
in vivo. Cancer Biol Ther. 2015;16(3):477-83. doi: 10.1080/15384047.2015.1016659.
PubMed PMID: 25700942; PubMed Central PMCID: PMC4623105.

2: Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, Giaccone G. Role and
relevance of TrkB mutations and expression in non-small cell lung cancer. Clin
Cancer Res. 2011 May 1;17(9):2638-45. doi: 10.1158/1078-0432.CCR-10-3034. PubMed
PMID: 21242122; PubMed Central PMCID: PMC3086954.

img

AZD-6918



Additional Information

Phase I clinical trial for AZD-6918 was started in 2009. However, AZD6918 was discontinued from development due to an unacceptable pharmacokinetic profile. Drug was discontinued in 2009.